From Polypharmacy to Precision Therapy: Why Is Deprescribing Gaining Global Attention?

With the acceleration of global population aging and the continuous rise in the burden of chronic diseases, polypharmacy has become a widespread challenge faced by healthcare systems worldwide.

In recent years, a new concept has been increasingly discussed in international medicine, pharmacy, and health policy circles—deprescribing.

Deprescribing does not simply mean reducing the number of medications. Rather, it refers to optimizing pharmacotherapy based on scientific evaluation, thereby achieving more precise and rational medication management.

So why has deprescribing become a global focus of attention? DengYueMed will systematically analyze this topic from the perspectives of polypharmacy burden, the trend toward precision therapy, and global rational medication management practices.

What Is Deprescribing?

Deprescribing is the process of systematic medication review conducted by a professional healthcare team, with the goal of adjusting, reducing, or discontinuing certain medications when appropriate.

Its core objectives include:

● Improving the rationality of pharmacotherapy

● Optimizing medication management for patients

● Reducing medication-related risks

● Enhancing healthcare resource utilization efficiency

● Supporting individualized treatment strategies

It is important to emphasize that deprescribing does not mean “less medication” or “stopping medication,” but rather achieving more precise drug allocation based on evidence-based medicine.

The Growing Burden of Polypharmacy Worldwide

In recent years, the global burden of chronic diseases has continued to increase.

Conditions such as hypertension, diabetes, cardiovascular diseases, chronic respiratory diseases, and cancer are becoming increasingly prevalent, leading many patients to require multiple medications simultaneously.

In particular, polypharmacy has become a common phenomenon among the elderly population.

Research indicates:

● Increasing prevalence of multimorbidity

● Rising long-term prescription medication use

● Aging population driving higher drug demand

● Growing complexity in medication management within healthcare systems

As the variety of medications continues to expand, ensuring that each drug continues to provide meaningful clinical value has become a critical issue in healthcare management.

Why Has Deprescribing Become a Global Focus?

1. Promoting Rational Use of Medicines

Rational use of medicines has always been a key goal of global healthcare systems.

As treatment regimens become increasingly complex, healthcare institutions are paying more attention to drug interactions, duplication, and long-term therapy management.

Deprescribing provides a structured framework for medication optimization, helping improve overall treatment management quality.

2. Advancing Precision Medicine

Precision medicine focuses not only on diseases but also on individual patient differences.

With the development of genetic testing, molecular diagnostics, and personalized therapies, healthcare is shifting from a “one-size-fits-all” model toward precision-based treatment.

In this context, deprescribing is considered an important component of precision therapy.

Through continuous evaluation of treatment regimens, healthcare providers can focus on interventions that deliver true clinical value.

3. Addressing Population Aging Challenges

According to the United Nations, the global elderly population is expected to continue growing over the coming decades.

Older patients typically face:

● Multiple chronic conditions

● Long-term medication use

● Increased complexity in medication management

As a result, many countries are incorporating deprescribing into geriatric care and pharmaceutical service systems.

4. Improving Healthcare Resource Efficiency

Global healthcare expenditure continues to rise.

Balancing healthcare quality with resource efficiency has become a key objective of healthcare reform worldwide.

Deprescribing contributes to:

● Rational allocation of pharmaceutical resources

● Improved healthcare service value

● Optimization of long-term care management

● Sustainability of healthcare systems

As a result, more healthcare institutions are establishing medication review mechanisms for patients with polypharmacy.

International Approaches to Deprescribing

Currently, many countries and regions have developed structured practices in this field.

For example:

● Canada pioneered Deprescribing Guidelines

● Australia integrated deprescribing into aged care systems

● The United Kingdom continues to promote medication optimization programs

● Several European countries have established pharmacist-led medication review systems

● The United States is strengthening research on polypharmacy management

These practices demonstrate that deprescribing is gradually evolving from academic discussion into clinical practice and health policy implementation.

What Does It Mean for the Pharmaceutical Industry?

The rise of deprescribing does not necessarily mean a decline in drug demand.

Instead, it is driving the industry from a “volume-driven” model toward a “value-driven” model.

Future competition in the pharmaceutical market will increasingly focus on:

1.  Real clinical value of drugs: Innovative therapies that consistently improve patient outcomes will gain more attention.

2.  Treatment optimization: Medicines are no longer standalone products but part of an integrated treatment system.

3.  Real-world evidence accumulation: Pharmaceutical companies must demonstrate long-term efficacy and safety through real-world data.

4.  Enhanced patient management services: Pharmacovigilance, disease management, and digital health solutions will see growing opportunities.

New Opportunities for Pharmaceutical Distributors

Under this global trend, pharmaceutical distribution is gradually evolving from a traditional supply chain role into a “healthcare value connector.”

For example, global pharmaceutical distributor DengYueMed is continuously focusing on:

● International innovative drug distribution systems

● Improved drug accessibility for healthcare institutions

● Global trends in rational medication use

● Pharmaceutical supply chain efficiency enhancement

● Cross-border healthcare resource connectivity

This transformation reflects the emerging role of pharmaceutical distributors in the era of precision medicine.

Conclusion

From polypharmacy to precision therapy, deprescribing is becoming an important direction in the evolution of global healthcare systems.

This trend not only changes the way medications are used but also drives healthcare systems toward a shift from treatment-oriented to value-oriented models.

For healthcare institutions, pharmaceutical companies, and pharmaceutical distributors alike, deprescribing represents not just an optimization of medication management, but a key pathway toward a more precise and sustainable global healthcare system.

In this process, Hong Kong-based DengYueMed will continue to monitor industry developments and global healthcare trends, aiming to connect global pharmaceutical and medical resources and support the advancement of rational medication use and precision therapy.